Table 4.
Clinical Investigations | Tocilizumab (n = 110) (1) |
Control (n = 630) (1) |
p Value (2) | |
---|---|---|---|---|
CT Scan Findings | Ground glass opacity | 53 (48.2%) | 352 (55.9%) | 0.001 F |
Infiltrations | 2 (1%) | 19 (3%) | ||
Major abnormality | 14 (12.7%) | 80 (12.7%) | ||
Mixed ground glass opacity and Infiltrations | 37 (33.6%) | 66 (10.5%) | ||
Patchy shadowing | 4 (3.6%) | 113 (17.9%) |
(1) n (%); (2) F = Fisher’s exact test.